Development asset linked to Farmatek in public FDA and regional records.
pharma · Hematologic Malignancies · Solid Tumor, Adult
Farmatek
Zafatek
Farmatek drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP HQ
1994 Founded
14 Employees
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP
- Founded
- 1994
- Employees
- 14
- Programs
- 26
- Drugs
- 14
- Patents
- 53
Farmatek pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Farmatek drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Farmatek in public FDA and regional records.
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Farmatek in public FDA and regional records.
-
Development asset linked to Farmatek in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Farmatek in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Farmatek in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Farmatek in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Farmatek in public FDA and regional records.